mirabegron   Click here for help

GtoPdb Ligand ID: 7445

Synonyms: Betmiga® | Myrbetriq® | YM-178
Approved drug PDB Ligand
mirabegron is an approved drug (FDA and EMA (2012))
Compound class: Synthetic organic
Comment: Mirabegron is a β3-adrenoceptor agonist muscle relaxant. It has been reported to exert effects on cellular metabolism in adipocytes. This latter action is β3-adrenoceptor-dependent, and improves glucose handling in vivo [5].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: mirabegron

mirabegron is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 4
Rotatable bonds 10
Topological polar surface area 128.51
Molecular weight 396.16
XLogP 1.66
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES O=C(Cc1csc(n1)N)Nc1ccc(cc1)CCNCC(c1ccccc1)O
Isomeric SMILES O=C(Cc1csc(n1)N)Nc1ccc(cc1)CCNC[C@@H](c1ccccc1)O
InChI InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1
InChI Key PBAPPPCECJKMCM-IBGZPJMESA-N
References
1. Badawi JK, Seja T, Uecelehan H, Honeck P, Kwon ST, Bross S, Langbein S. (2007)
Relaxation of human detrusor muscle by selective beta-2 and beta-3 agonists and endogenous catecholamines.
Urology, 69 (4): 785-90. [PMID:17445682]
2. Brucker BM, King J, Mudd Jr PN, McHale K. (2022)
Selectivity and Maximum Response of Vibegron and Mirabegron for β3-Adrenergic Receptors.
Curr Ther Res Clin Exp, 96: 100674. [PMID:35693456]
3. Dehvari N, da Silva Junior ED, Bengtsson T, Hutchinson DS. (2018)
Mirabegron: potential off target effects and uses beyond the bladder.
Br J Pharmacol, 175 (21): 4072-4082. [PMID:29243229]
4. Dehvari N, Sato M, Bokhari MH, Kalinovich A, Ham S, Gao J, Nguyen HTM, Whiting L, Mukaida S, Merlin J et al.. (2020)
The metabolic effects of mirabegron are mediated primarily by β3 -adrenoceptors.
Pharmacol Res Perspect, 8 (5): e00643. [PMID:32813332]
5. Dehvari N, Sato M, Bokhari MH, Kalinovich A, Ham S, Gao J, Nguyen HTM, Whiting L, Mukaida S, Merlin J et al.. (2020)
The metabolic effects of mirabegron are mediated primarily by β3‐adrenoceptors.
Pharmacology Research & Perspectives, 8 (5): e00643. DOI: 10.1002/prp2.643
6. Hatanaka T, Ukai M, Watanabe M, Someya A, Ohtake A, Suzuki M, Ueshima K, Sato S, Sasamata M. (2013)
In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats.
Naunyn Schmiedebergs Arch Pharmacol, 386 (3): 247-53. [PMID:23239087]
7. Nomiya M, Yamaguchi O. (2003)
A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders.
J Urol, 170 (2 Pt 1): 649-53. [PMID:12853849]
8. Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, Yamaguchi O. (2007)
Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.
J Pharmacol Exp Ther, 321 (2): 642-7. [PMID:17293563]
9. Yamaguchi O. (2002)
Beta3-adrenoceptors in human detrusor muscle.
Urology, 59 (5 Suppl 1): 25-9. [PMID:12007519]